RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Revenue

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndRevenue (Million USD)YoY (%)
Dec 31, 2024167+27.28%
Dec 31, 2023131-33.09%
Dec 31, 2022196-29.19%
Dec 31, 2021277+48.66%
Dec 31, 2020186+54.98%
Dec 31, 2019120-52.17%
Dec 31, 2018251+78.21%
Dec 31, 2017141+29.48%
Dec 31, 2016109+51.53%
Dec 31, 201572+11.43%
Dec 31, 201465+31.78%
Dec 31, 201349+56.02%
Dec 31, 201231+4.50%
Dec 31, 201130

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)